TOMZ

TOMZ is a $17M micro-cap whose FY2025 numbers describe a company running on fumes. Revenue fell 27.2% to $5.64M, and this is not a one-year stumble: sales have now dropped from $8.34M (FY2022) to $5.64M, while the company has lost money every single year in the 2021–2025 window (-$4.44M, -$2.88M, -$3.40M, -$4.48M, -$3.75M). Management frames the decline as 'timing of large equipment purchases' and tariff-related delays in pharma facility construction, but with no long-term customer contracts (explicitly flagged in Risk Factors — customers 'may cease purchasing at any time without penalty') and a razor-thin backlog, there is no contractual floor under revenue. Operating margin is -68.4% and net margin -66.5%; the business consumed $1.20M of operating cash in the year.

The balance sheet is the disqualifier. Stockholders' equity collapsed 85.6% to just $589K against $6.45M of liabilities — a 10.95x liabilities/equity ratio — and cash is down to $87.8K, an 86.8% drawdown. An accumulated deficit of $58.1M sits against essentially no equity cushion; ROE of -637% is arithmetically meaningless but directionally screams near-insolvency. With $88K of cash and a $1.2M annual burn, the company cannot self-fund, and it says so: it is 'pursuing additional financing through equity and convertible debt,' including a $20M equity line of credit (ELOC) with Hudson Global Ventures signed November 2025. An ELOC against a 20.5M-share, sub-$1 float is a dilution machine — existing holders will be ground down as the company sells stock into weakness to keep the lights on.